It is indeed now known that BRAF and RAS mutations and RET/PTC and PAX8/PPAR? rearrangements account for the majority of molecular alterations detected in differentiated thyroid cancers.     ///    "Testing for a ""panel of mutations"" (BRAF, RAS, RET/PTC and PAX8/PPAR?) improves the performance, detecting papillary carcinomas with non-classic histology. "